Pharmacotherapy for body dysmorphic disorder

Psychiatric Annals

Volumn 40, Issue 7, 2010, Pages 325-332

  Phillips, Katharine A ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77954821547     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/00485713-20100701-05     Document Type: Article

References (44)

1. National Collaborating Centre for Mental Health. Core interventions in the treatment of obsessive compulsive disorder and body dysmorphic disorder (a guideline from the National Institute for Health and Clinical Excellence, National Health Service). 2006. Accessed June 28, 2010. www.nice.org.uk/page. aspx?o=289817.
2. Ipser J, Sander C, Stein D. Pharmacotherapy and psychotherapy for body dysmorphic disorder. Cochrane Database Syst Rev. 2009 21(1);CD005332.
3. Phillips KA. Understanding Body Dysmorphic Disorder: An Essential Guide. New York, NY: Oxford University Press; 2009.
4. Phillips KA, Pagano ME, Menard W. Pharmacotherapy for body dysmorphic disorder: treatment received and illness severity. Ann Clin Psychiatry. 2006;18(4):251-257.
5. Phillips KA, Dwight MM, McElroy SL. Efficacy and safety of fluvoxamine in body dysmorphic disorder. J Clin Psychiatry. 1998;59(4):165-171.
6. Eisen JL, Phillips KA, Coles ME, Rasmussen SA. Insight in obsessive compulsive disorder and body dysmorphic disorder. Compr Psychiatry. 2004;45(1):10-15.
7. Wilhelm S, Phillips KA, Steketee G. Cognitive-Behavioral Therapy for Body Dysmorphic Disorder: A Modular Treatment Manual. New York, NY: Guilford Press, Inc. In press.
8. Miller WR, Rollnick S. Motivational Interviewing: Preparing People to Change Addictive Behavior. New York, NY: Guilford Press; 1991.
9. Phillips KA, Hollander E. Treating body dysmorphic disorder with medication: Evidence, misconceptions, and a suggested approach. Body Image. 2008;5(1):13-27.
10. Brady KT, Austin L, Lydiard RB. Body dysmorphic disorder: the relationship to obsessive-compulsive disorder. J Nerv Ment Dis. 1990;178(8):538-540.
11. Hollander E, Liebowitz MR, Winchel R, Klumker A, Klein DF. Treatment of body-dysmorphic disorder with serotonin reuptake blockers. Am J Psychiatry. 1989;146(6):768-770.
12. Phillips KA. Body dysmorphic disorder: the distress of imagined ugliness. Am J Psychiatry. 1991;148(9):1138-1149.
13. Phillips KA, McElroy SL, Keck PE, Pope HG, Hudson JI. Body dysmorphic disorder: 30 cases of imagined ugliness. Am J Psychiatry. 1993;150(2):302-308.
14. Phillips KA, McElroy SL, Keck PE, Pope HG, Hudson JI. A comparison of delusional and nondelusional body dysmorphic disorder in 100 cases. Psychopharmacol Bull. 1994;30(2):179-186.
15. Hollander E, Allen A, Kwon J, et al. Clomipramine vs desipramine crossover trial in body dysmorphic disorder: selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Arch Gen Psychiatry. 1999;56(11):1033-1039.
16. Phillips KA, Albertini RS, Rasmussen SA. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Arch Gen Psychiatry. 2002;59(4):381-388.
17. Phillips KA, Rasmussen SA. Change in psychosocial functioning and quality of life of patients with body dysmorphic disorder treated with fluoxetine: a placebo-controlled study. Psychosomatics. 2004;45(5):438-444.
18. Perugi G, Giannotti D, Di Vaio S, Frare F, Saettoni M, Cassano GB. Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphophobia). Int Clin Psychopharmacol. 1996;11(4):247-254.
19. Phillips KA. An open-label study of escitalopram in body dysmorphic disorder. Int Clin Psychopharmacol. 2006;21(3):177-179.
20. Phillips KA, Najar F. An open-label study of citalopram in body dysmorphic disorder. J Clin Psychiatry. 2003;64(6):715-720.
21. Phillips KA, Siniscalchi JM, McElroy SL. Depression, anxiety, anger, and somatic symptoms in patients with body dysmorphic disorder. Psychiatric Q. 2004;75(4):309-320.
22. Phillips KA, Kelly MM. Suicidality in a placebo-controlled fluoxetine study of body dysmorphic disorder. Int Clin Psychopharmacol. 2009;24(1):26-28.
23. Veale D, Boocock A, Gournay K, Dryden W. Body dysmorphic disorder: a survey of fifty cases. Br J Psychiatry. 1996;169(2):196-201.
24. Phillips KA, Coles ME, Menard W, Yen S, Fay C, Weisberg RB. Suicidal ideation and suicide attempts in body dysmorphic disorder. J Clin Psychiatry. 2005;66(6):717-725.
25. Phillips KA, Menard W. Suicidality in body dysmorphic disorder: a prospective study. Am J Psychiatry. 2006;163(7):1280-1282.
26. Phillips KA, Albertini RS, Siniscalchi JM, Khan A, Robinson M. Effectiveness of pharmacotherapy for body dysmorphic disorder: a chart-review study. J Clin Psychiatry. 2001;62(9):721-727.
27. Albertini RS, Phillips KA, Guevremont D. Body dysmorphic disorder in a young child (letter). J Am Acad Child Adolesc Psychiatry. 1996;35(11):1425-1426.
28. El-khatib HE, Dickey T. Sertraline for body dysmorphic disorder. J Am Acad Child Adolesc Psychiatry. 1995;34(11):1404-1405.
29. Heimann SW. SSRI for body dysmorphic disorder. J Am Acad Child Adolesc Psychiatry. 1997;36(7):868.
30. Sondheimer A. Clomipramine treatment of delusional disorder-somatic type. J Am Acad Child Adolesc Psychiatry. 1988;27(2):188-192.
31. Albertini RS, Phillips KA. Thirty-three cases of body dysmorphic disorder in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1999;38(4):453-459.
32. Phillips KA, McElroy SL, Dwight MM, Eisen JL, Rasmussen SA. Delusionality and response to open-label fluvoxamine in body dysmorphic disorder. J Clin Psychiatry. 2001;62(2):87-91.
33. Phillips KA. The Broken Mirror: Understanding and Treating Body Dysmorphic Disorder. (Revised and expanded edition). New York, NY: Oxford University Press; 2005.
34. Phillips KA. Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder. Am J Psychiatry. 2005;162(2):377-379.
35. Phillips KA. Olanzapine augmentation of fluoxetine in body dysmorphic disorder (letter). Am J Psychiatry. 2005;162(5):1022-1023.
36. Phillips KA. An open study of buspirone augmentation of serotonin-reuptake inhibitors in body dysmorphic disorder. Psychopharmacol Bull. 1996;32(1):175-180.
37. Phillips KA, Menard W. A Prospective pilot study of levetiracetam for body dysmorphic disorder. CNS Spectr. 2009;14(5):252-260.
38. Allen A, Hadley SJ, Kaplan A, et al. An openlabel trial of venlafaxine in body dysmorphic disorder. CNS Spectr. 2008;13(2):138-144.
39. Hollander E, Cohen LJ, Simeon D, Rosen J, deCaria CM, Stein D. Fluvoxamine treatment of body dysmorphic disorder. J Clin Psychopharmacol. 1994;14(1):75-77.
40. Phillips KA. Pharmacologic treatment of body dysmorphic disorder. Psychopharmacol Bull. 1996;32(4):597-605.
41. Hay G. Dysmorphophobia. Br J Psychiatry. 1970;116(533):399-406.
42. Mindus P. Personal communication.
43. Cassem E. Personal communication.
44. Rassmussen S. Personal communication.